Tissue Engineered Models of Brain Tumors and Their Applications

95

elucidate diverse aspects of the tumor biology and to create biobanks. This

extensive effort expanded the survival of patients about two years, yet promis-

ing results can be achieved with the development of more realistic models for

clinics and the area is gradually expanding with encouraging outcomes. In the

current state, we still search for the discovery of the cure for GBM and there

is an urgent need to address not only tumor eradication, but also metastasis

and recurrence. New designs contributed by computational models (molecular

docking, disease models) and single-cell analysis can be future of GBM model-

ing and perhaps, pre-clinical drug test environment. Obtained information is

an opportunity to analyze the applicability and reliability of these treatments

to recurrent or metastatic carcinoma and other groups of cancer.

Bibliography

[1] D. N. Louis, A. Perry, and P. Wesseling et al., “The 2021 WHO clas-

sification of tumors of the central nervous system: a summary,” Neuro-

Oncology, vol. 23, no. 8, pp. 1231–1251, 2021.

[2] S. DeCordova, A. Shastri, and A. G. Tsolaki et al., “Molecular het-

erogeneity and immunosuppressive microenvironment in glioblastoma,”

Frontiers in Immunology, vol. 11, p. 1402, 2020.

[3] K. J. Wolf, J. Chen, and J. D. Coombes et al., “Dissecting and rebuilding

the glioblastoma microenvironment with engineered materials,” Nature

Reviews Materials, vol. 4, no. 10, pp. 651–668, 2019.

[4] D. F. Quail and J. A. Joyce, “The microenvironmental landscape of

brain tumors,” Cancer Cell, vol. 31, no. 3, pp. 326–341, 2017.

[5] H. J. Kim, J. W. Park, and J. H. Lee, “Genetic architectures and cell-of-

origin in glioblastoma,” Frontiers in Oncology, vol. 10, p. 615400, 2021.

[6] S. Ma, S. Rudra, and J. L. Campian et al., “Prognostic impact of

CDKN2A/B deletion, TERT mutation, and EGFR amplification on his-

tological and molecular IDH-wildtype glioblastoma,” Neuro-Oncology

Advances, vol. 2, no. 1, p. vdaa126, 2020.

[7] A. Wenger, S. Ferreyra Vega, and T. Kling et al., “Intratumor

DNA methylation heterogeneity in glioblastoma: implications for

DNA methylation-based classification,” Neuro-Oncology, vol. 21, no. 5,

pp. 616–627, 2019.

[8] K. Biserova, A. Jakovlevs, and R. Uljanovs et al., “Cancer stem cells: sig-

nificance in origin, pathogenesis and treatment of glioblastoma,” Cells,

vol. 10, no. 3, p. 621, 2021.